| 李华伟,李 萌,刘 强.重组人血管内皮抑制素联合化疗治疗晚期小细胞肺癌的疗效及安全性Meta分析[J].肿瘤学杂志,2020,26(7):630-637. |
| 重组人血管内皮抑制素联合化疗治疗晚期小细胞肺癌的疗效及安全性Meta分析 |
| A Meta Analysis of rh-Endostatin Combined with Chemotherapy for Advanced Small Cell Lung Cancer |
| 投稿时间：2019-09-22 |
| DOI：10.11735/j.issn.1671-170X.2020.07.B013 |
|
 |
| 中文关键词: 重组人血管内皮抑制素 小细胞肺癌 化疗 meta分析 |
| 英文关键词:rh-endostatin small cell lung cancer chemotherapy meta analysis |
| 基金项目: |
|
| 摘要点击次数: 1209 |
| 全文下载次数: 237 |
| 中文摘要: |
| 摘 要： ［目的］ 评价重组人血管内皮抑制素联合化疗治疗晚期小细胞肺癌的有效性和安全性。［方法］ 检索Cochrane图书馆、PubMed、EMbase、中国知网、万方数据库、中国生物医学文献数据库，收集重组人血管内皮抑制素联合化疗对比单纯化疗治疗晚期小细胞肺癌的随机对照试验，采用RevMan 5.3软件进行Meta分析。［结果］ 共纳入9篇文献，合计661例病例。Meta分析结果显示，重组人血管内皮抑制素联合化疗与单纯化疗相比，联合治疗在客观缓解率（RR=1.37，95%CI：1.21～1.55，P＜0.001）、疾病控制率（RR=1.14，95%CI：1.06～1.22，P=0.0007）方面均显示出优势。提高了半年的PFS（RR=1.83，95%CI：1.12～3.01，P=0.02）和1年PFS（RR=3.67，95%CI：1.72～7.86，P=0.0008）。延长了2年OS（RR=3.53，95%CI：1.74～7.14，P=0.0005），但1年OS无统计学差异（RR=1.26，95%CI：0.86～1.83，P=0.24）。不良反应方面，联合化疗组和单纯化疗组在白细胞减少、血小板减少、血红蛋白减少、肝肾功能损害和胃肠道反应方面差异均无统计学意义。［结论］ 重组人血管内皮抑制素联合化疗治疗晚期小细胞肺癌安全有效。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the efficacy and safety of rh-endostatin plus chemotherapy in the treatment of advanced small cell lung cancer(SCLC). ［Methods］ The randomized controlled trials on rh-endostatin combined chemotherapy for advanced SCLC were searched from PubMed，EMbase，Cochrane library，CNKI，Chinese biomedical literature database and Wanfang database. RevMan 5.3 software was used to analyze studies that met the inclusion criteria. ［Results］ Nine clinical trials involving 661 patients with advanced SCLC were included. Meta analysis results suggested that the objective response rate and disease control rate of the rh-endostatin combined with chemotherapy was higher than that of chemotherapy alone group(RR=1.37，95%CI：1.21~1.55，P<0.001；RR=1.14，95%CI：1.06~1.22，P=0.0007，respectively). It increased the PFS for half a year(RR=1.83，95% CI：1.12～3.01，P=0.02) and the PFS for 1-year(RR=3.67，95%CI：1.72～7.86，P=0.0008). The 2-year OS was extended(RR=3.53，95%CI：1.74～7.14，P=0.0005)，but there was no significant difference in 1-year OS(RR=1.26，95%CI：0.86～1.86，P=0.24). There were no significant differences between the two groups in the occurrence of leukopenia，thrombocytopenia，hemoglobin reduction，liver and kidney function damage and gastrointestinal reactions.［Conclusion］ rh-Endostatin plus chemotherapy in the treatment of advanced small cell lung cancer is safe and effective． |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |